Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$4.96
+0.5%
$8.24
$4.36
$94.50
$8.99M0.51143,929 shs12,893 shs
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
$0.97
$0.37
$1.67
$8K-0.39525,982 shs432 shs
Medicure Inc. stock logo
MCUJF
Medicure
$0.86
-5.5%
$0.78
$0.44
$0.94
$8.99M1.06575 shs100 shs
VIVUS, Inc. stock logo
VVUS
VIVUS
$0.37
$0.44
$4.75
$7.33M-0.841.44 million shs2.03 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
+1.65%+2.26%-55.09%-41.14%-93.01%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Medicure Inc. stock logo
MCUJF
Medicure
0.00%-5.48%-0.17%+59.54%-4.28%
VIVUS, Inc. stock logo
VVUS
VIVUS
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3.5196 of 5 stars
3.25.00.00.02.71.71.3
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
VIVUS, Inc. stock logo
VVUS
VIVUS
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$375.007,466.59% Upside
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
0.00
N/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
0.00
N/AN/AN/A
VIVUS, Inc. stock logo
VVUS
VIVUS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLRB, MCUJF, INNT, and VVUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$8.98 per shareN/A
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/AN/AN/AN/A($0.27) per shareN/A
Medicure Inc. stock logo
MCUJF
Medicure
$15.99M0.56$0.09 per share9.66$1.45 per share0.59
VIVUS, Inc. stock logo
VVUS
VIVUS
$69.76M0.00N/AN/A($6.50) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/A
Medicure Inc. stock logo
MCUJF
Medicure
-$760K-$0.13N/AN/A-8.15%-8.74%-6.05%8/12/2025 (Estimated)
VIVUS, Inc. stock logo
VVUS
VIVUS
-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/A

Latest CLRB, MCUJF, INNT, and VVUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Medicure Inc. stock logo
MCUJF
Medicure
N/A-$0.05N/A-$0.05N/A$3.82 million
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$5.10-$3.90+$1.20-$0.14N/AN/A
4/25/2025Q4 2024
Medicure Inc. stock logo
MCUJF
Medicure
N/A-$0.04N/A-$0.04N/A$4.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/AN/AN/AN/AN/A
Medicure Inc. stock logo
MCUJF
Medicure
N/AN/AN/AN/AN/A
VIVUS, Inc. stock logo
VVUS
VIVUS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
2.47
2.47
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/A
0.35
0.35
Medicure Inc. stock logo
MCUJF
Medicure
0.02
1.71
1.29
VIVUS, Inc. stock logo
VVUS
VIVUS
N/A
0.43
0.28

Institutional Ownership

CompanyInstitutional Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
5.88%
Medicure Inc. stock logo
MCUJF
Medicure
N/A
VIVUS, Inc. stock logo
VVUS
VIVUS
7.32%

Insider Ownership

CompanyInsider Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
5.04%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
7.90%
Medicure Inc. stock logo
MCUJF
Medicure
12.90%
VIVUS, Inc. stock logo
VVUS
VIVUS
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
101.81 million1.72 millionOptionable
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
841.33 millionN/ANot Optionable
Medicure Inc. stock logo
MCUJF
Medicure
N/A10.44 million9.09 millionNot Optionable
VIVUS, Inc. stock logo
VVUS
VIVUS
5717.87 millionN/AOptionable

Recent News About These Companies

VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS Shares Significant Regulatory Update on QSYMIA®
VIVUS Announces Label Update for QSYMIA®
VIVUS Provides Update on Pipeline and Program Milestones

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$4.96 +0.03 (+0.53%)
As of 10:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Innovate Biopharmaceuticals stock logo

Innovate Biopharmaceuticals NASDAQ:INNT

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Medicure stock logo

Medicure OTCMKTS:MCUJF

$0.86 -0.05 (-5.54%)
As of 07/8/2025 03:23 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

VIVUS stock logo

VIVUS NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.